 Anti-HIV Agents
"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1998 | 1 | 4 | 5 | | 1999 | 2 | 1 | 3 | | 2000 | 2 | 0 | 2 | | 2001 | 2 | 1 | 3 | | 2002 | 2 | 2 | 4 | | 2003 | 5 | 2 | 7 | | 2004 | 9 | 1 | 10 | | 2005 | 8 | 2 | 10 | | 2006 | 4 | 2 | 6 | | 2007 | 4 | 1 | 5 | | 2008 | 9 | 1 | 10 | | 2009 | 7 | 2 | 9 | | 2010 | 10 | 1 | 11 | | 2011 | 6 | 7 | 13 | | 2012 | 14 | 2 | 16 | | 2013 | 11 | 2 | 13 | | 2014 | 12 | 6 | 18 | | 2015 | 8 | 5 | 13 | | 2016 | 25 | 10 | 35 | | 2017 | 17 | 7 | 24 | | 2018 | 14 | 5 | 19 | | 2019 | 14 | 3 | 17 | | 2020 | 21 | 5 | 26 | | 2021 | 25 | 5 | 30 | | 2022 | 13 | 0 | 13 |
To return to the timeline, click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Brooks KM, Pinilla M, Stek AM, Shapiro DE, Barr E, Febo IL, Paul ME, Deville JG, George K, Knowles K, Rungruengthanakit K, Browning R, Chakhtoura N, Capparelli EV, Mirochnick M, Best BM. Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s. J Acquir Immune Defic Syndr. 2022 07 01; 90(3):343-350.
-
Celum CL, Bukusi EA, Bekker LG, Delany-Moretlwe S, Kidoguchi L, Omollo V, Rousseau E, Travill D, Morton JF, Mogaka F, O'Malley G, Barnabee G, van der Straten A, Donnell D, Parikh UM, Kudrick L, Anderson PL, Haberer JE, Wu L, Heffron R, Johnson R, Morrison S, Baeten JM. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project. J Int AIDS Soc. 2022 Jul; 25(7):e25962.
-
Eshleman SH, Fogel JM, Piwowar-Manning E, Chau G, Cummings V, Agyei Y, Richardson P, Sullivan P, Haines CD, Bushman LR, Petropoulos C, Persaud D, Kofron R, Hendrix CW, Anderson PL, Farrior J, Mellors J, Adeyeye A, Rinehart A, St Clair M, Ford S, Rooney JF, Mathew CA, Hunidzarira P, Spooner E, Mpendo J, Nair G, Cohen MS, Hughes JP, Hosseinipour M, Hanscom B, Delany-Moretlwe S, Marzinke MA. Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. J Infect Dis. 2022 05 16; 225(10):1741-1749.
-
Giovenco D, Pettifor A, Powers KA, Hightow-Weidman L, Pence BW, Celum C, Delany-Moretlwe S, Hosek S, Donnell D, Anderson PL, Mgodi N, Bekker LG. Intimate partner violence and oral HIV pre-exposure prophylaxis adherence among young African women. AIDS. 2022 Jul 01; 36(8):1151-1159.
-
Bracho-Sanchez E, Stonbraker S, Halpern M, Wood S, Lowenthal E. HIV pre-exposure prophylaxis: assessment of acceptability among members of HIV serodiscordant/serostatus unknown couples. Int J STD AIDS. 2022 06; 33(7):687-693.
-
Weinberg A, Giganti MJ, Sirois PA, Montepiedra G, Canniff J, Agwu A, Boivin MJ, Kapetanovic S, Abzug MJ. Coordination of inflammatory responses in children with perinatally acquired HIV infection. AIDS. 2022 Jul 01; 36(8):1117-1127.
-
Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Spooner E, Mpendo J, Mukwekwerere P, Mgodi N, Ntege PN, Nair G, Nakabiito C, Nuwagaba-Biribonwoha H, Panchia R, Singh N, Siziba B, Farrior J, Rose S, Anderson PL, Eshleman SH, Marzinke MA, Hendrix CW, Beigel-Orme S, Hosek S, Tolley E, Sista N, Adeyeye A, Rooney JF, Rinehart A, Spreen WR, Smith K, Hanscom B, Cohen MS, Hosseinipour MC. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022 05 07; 399(10337):1779-1789.
-
Haberer JE, Mugo N, Bukusi EA, Ngure K, Kiptinness C, Oware K, Garrison LE, Musinguzi N, Pyra M, Valenzuela S, Thomas KK, Anderson PL, Thirumurthy H, Baeten JM. Understanding Pre-Exposure Prophylaxis Adherence in Young Women in Kenya. J Acquir Immune Defic Syndr. 2022 03 01; 89(3):251-260.
-
Jalil EM, Torres TS, Luz PM, Monteiro L, Moreira RI, de Castro CRV, Leite IDC, Cunha M, de Cássia Elias Estrela R, Ramos M, Hoagland B, Wagner Cardoso S, Anderson P, Veloso VG, Wilson E, Grinsztejn B. Low PrEP adherence despite high retention among transgender women in Brazil: the PrEParadas study. J Int AIDS Soc. 2022 03; 25(3):e25896.
-
Lee JS, Humes E, Hogan BC, Justice AC, Klein M, Gebo K, John Gill M, Silverberg MJ, Rebeiro P, Horberg M, Karris M, Rabkin C, Moore RD, Althoff KN. Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004-18: a cohort study. Lancet HIV. 2022 03; 9 Suppl 1:S2.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|